{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:56:37Z","timestamp":1791388597000,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1124\/jpet.121.000956","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T22:40:21Z","timestamp":1639176021000},"page":"230-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Empagliflozin Protects against Pulmonary Ischemia\/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism"],"prefix":"10.1016","volume":"380","author":[{"given":"Dou","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey W.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000956_bib1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000956_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/cells10061333","article-title":"Ischemia-reperfusion injury in lung transplantation","volume":"10","author":"Chen-Yoshikawa","year":"2021","journal-title":"Cells"},{"key":"10.1124\/jpet.121.000956_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","volume":"524","author":"Chowdhury","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.121.000956_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1164\/rccm.200207-670SO","article-title":"Ischemia-reperfusion-induced lung injury","volume":"167","author":"de Perrot","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/jpet.121.000956_bib5","doi-asserted-by":"crossref","first-page":"F47","DOI":"10.1152\/ajprenal.00092.2021","article-title":"SGLT2 inhibitors, hemodynamics, and kidney protection","volume":"321","author":"Ellison","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.121.000956_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1089\/ars.2010.3360","article-title":"Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin","volume":"14","author":"Hausenloy","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/jpet.121.000956_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10741-007-9026-1","article-title":"Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection","volume":"12","author":"Hausenloy","year":"2007","journal-title":"Heart Fail Rev"},{"key":"10.1124\/jpet.121.000956_bib8","doi-asserted-by":"crossref","first-page":"L579","DOI":"10.1152\/ajplung.00381.2016","article-title":"Higher mini-BAL total protein concentration in early ARDS predicts faster resolution of lung injury measured by more ventilator-free days","volume":"312","author":"Hendrickson","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1124\/jpet.121.000956_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1124\/jpet.121.000956_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165123","article-title":"Remote liver ischemic preconditioning protects against sudden cardiac death via an ERK\/GSK-3\u03b2-dependent mechanism","volume":"11","author":"Hu","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.121.000956_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","article-title":"Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death","volume":"20","author":"Hu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/jpet.121.000956_bib12","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"10.1124\/jpet.121.000956_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"10.1124\/jpet.121.000956_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2019.103316","article-title":"Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis","volume":"273","author":"Kabel","year":"2020","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1124\/jpet.121.000956_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.121.000956_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","article-title":"Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury","volume":"19","author":"Lahnwong","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/jpet.121.000956_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2009.03.019","article-title":"Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway?","volume":"47","author":"Lecour","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/jpet.121.000956_bib18","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2147\/JIR.S309427","article-title":"Empagliflozin alleviates atherosclerosis progression by inhibiting inflammation and sympathetic activity in a normoglycemic mouse model","volume":"14","author":"Liu","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1124\/jpet.121.000956_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110642","article-title":"Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway","volume":"501","author":"Lu","year":"2020","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.121.000956_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196186","article-title":"Remote ischemic preconditioning STAT3-dependently ameliorates pulmonary ischemia\/reperfusion injury","volume":"13","author":"Luo","year":"2018","journal-title":"PLoS One"},{"key":"10.1124\/jpet.121.000956_bib21","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.121.000956_bib22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1165\/rcmb.2009-0210ST","article-title":"An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals","volume":"44","author":"Matute-Bello","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1124\/jpet.121.000956_bib23","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000956_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000956_bib25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/jpet.118.253666","article-title":"Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats","volume":"368","author":"Oshima","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.121.000956_bib26","doi-asserted-by":"crossref","first-page":"15601","DOI":"10.1038\/s41598-019-51648-1","article-title":"Empagliflozin and dulaglutide are effective against obesity-induced airway hyperresponsiveness and fibrosis in a murine model","volume":"9","author":"Park","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.121.000956_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/jpet.121.000956_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/jpet.121.000956_bib29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2337\/db19-0888","article-title":"Interindividual heterogeneity of SGLT2 expression and function in human pancreatic islets","volume":"69","author":"Saponaro","year":"2020","journal-title":"Diabetes"},{"key":"10.1124\/jpet.121.000956_bib30","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.numecd.2020.05.030","article-title":"Sodium-glucose co-transporter-2 inhibitors: peculiar \u201chybrid\u201d diuretics that protect from target organ damage and cardiovascular events","volume":"30","author":"Sarzani","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1124\/jpet.121.000956_bib31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1582-4934.2004.tb00476.x","article-title":"Role of STAT-1 and STAT-3 in ischaemia\/reperfusion injury","volume":"8","author":"Stephanou","year":"2004","journal-title":"J Cell Mol Med"},{"key":"10.1124\/jpet.121.000956_bib32","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1124\/jpet.121.000956_bib33","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.121.000956_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/mutage\/gew046","article-title":"Surface modification does not influence the genotoxic and inflammatory effects of TiO2 nanoparticles after pulmonary exposure by instillation in mice","volume":"32","author":"Wallin","year":"2017","journal-title":"Mutagenesis"},{"key":"10.1124\/jpet.121.000956_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000956_bib36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.33160\/yam.2019.03.005","article-title":"Protective effects of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, on a non-alcoholic steatohepatitis mouse model","volume":"62","author":"Yamane","year":"2019","journal-title":"Yonago Acta Med"},{"key":"10.1124\/jpet.121.000956_bib37","doi-asserted-by":"crossref","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","article-title":"Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney","volume":"270","author":"You","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.121.000956_bib38","doi-asserted-by":"crossref","first-page":"9762","DOI":"10.1096\/fj.201802519R","article-title":"The KCNE2 potassium channel \u03b2 subunit is required for normal lung function and resilience to ischemia and reperfusion injury","volume":"33","author":"Zhou","year":"2019","journal-title":"FASEB J"},{"key":"10.1124\/jpet.121.000956_bib39","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524002465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:25:59Z","timestamp":1739971559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524002465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0022356524002465"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000956","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin Protects against Pulmonary Ischemia\/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}